ETD

Digital archive of theses discussed at the University of Pisa

 

Thesis etd-07262017-213830


Thesis type
Tesina di master di II livello
Author
KHALFA, ESAIM FADHEL
URN
etd-07262017-213830
Thesis title
Impieghi clinici nel mieloma multiplo Talidomide
Department
MEDICINA CLINICA E SPERIMENTALE
Course of study
SPERIMENTAZIONE CLINICA DEI FARMACI
Supervisors
relatore Prof. Danesi, Romano
Keywords
  • mieloma multiplo
  • multiple myeloma
  • velcade
  • prednisone
  • melphalan
Graduation session start date
19/12/2014
Availability
Full
Summary
In the clinic, I am following approximately 100 patients suffering from Multiple Myeloma (MM), treated with a single dose capsule daily containing (50- 100 mg) of the drug. Thalidomide has shown its efficacy in multiple myeloma, particularly in combination with cortisone. Currently it is used in combination with Melphalan and Prednisone (MPT) as first-line therapy or in combination with Dexamethasone (Dex-Tal) in relapsing patients. Bortezomib (Velcade®) is a very active drug in patients with multiple myeloma. It has been used in experimental protocols in various stages of the disease (first-line therapy or relapse). Many studies have shown a clear superiority of Bortezomib in combination with high-dose Dexamethasone or other drugs (Thalidomide, Doxorubicin, Cyclophosphamide), compared to conventional therapy.
File